Strategic Partnerships HALIX has recent high‑profile collaborations with AstraZeneca and RocketVax, signaling strong interest from global vaccine and biologics developers. Target opportunities could focus on expanding existing partnerships or introducing HALIX capabilities to other vaccine manufacturers seeking CMO/CDMO support for development and commercialization.

Vaccine & Gene Therapy Capabilities The company specializes in recombinant proteins, antibodies, viral vectors and vaccines and has facilities in Leiden Bio Science Park. Sales plays can emphasize HALIX as a one‑stop shop for GMP manufacturing, process development, and scale‑up across early to commercial stages for life‑threatening diseases.

Emerging Leadership New CEO appointment and recent leadership hires indicate a growth trajectory and formalized business development focus. Leverage this to position HALIX as a partner investing in scale, governance, and long‑term commitments to customers in biotech and pharma.

Global Readiness Active collaborations with multinational entities suggest capability and readiness to support global supply chains and pandemic preparedness. Target multinational biopharma and CROs seeking robust manufacturing and regulatory‑compliant CDMO support for worldwide distribution.

Growth Signals Reported revenue in the low‑to‑mid millions and a lean employee base indicate potential for scalable partnerships, such as milestone‑driven programs or co‑development deals, aligning HALIX’s capabilities with mid‑sized biotech companies aiming to accelerate clinical and commercial milestones.